119 related articles for article (PubMed ID: 34242401)
21. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S
Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874
[TBL] [Abstract][Full Text] [Related]
22. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
23. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
24. 'Monster cell' melanoma with pulmonary metastasis and cyclin D1 amplification.
Hawryluk EB; Baran JL; Gerami P; Sepehr A
J Cutan Pathol; 2013 Jan; 40(1):61-5. PubMed ID: 23278726
[TBL] [Abstract][Full Text] [Related]
25. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
[TBL] [Abstract][Full Text] [Related]
26. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas.
Takata M; Goto Y; Ichii N; Yamaura M; Murata H; Koga H; Fujimoto A; Saida T
J Invest Dermatol; 2005 Aug; 125(2):318-22. PubMed ID: 16098043
[TBL] [Abstract][Full Text] [Related]
27. High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma.
Ekedahl H; Lauss M; Olsson H; Griewank KG; Schadendorf D; Ingvar C; Jönsson G
Pigment Cell Melanoma Res; 2016 Sep; 29(5):598-600. PubMed ID: 27301352
[No Abstract] [Full Text] [Related]
28. Comment on "Clinical genetic testing for familial melanoma in Italy: a cooperative study".
Amato A; Russo A; Adamo V; Cannavò SP
J Am Acad Dermatol; 2010 Dec; 63(6):1099. PubMed ID: 21093666
[No Abstract] [Full Text] [Related]
29. [Acral lentiginous melanoma: the current state of the problem].
Myasnyankin MY; Gafton GI; Anisimov VV; Matsko DE; Imyanitov EN; Semiletova YV
Vopr Onkol; 2015; 61(4):563-70. PubMed ID: 26571823
[TBL] [Abstract][Full Text] [Related]
30. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
31. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
Mrhalová M; Kodet R; Strnad P
Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
[TBL] [Abstract][Full Text] [Related]
32. [Fluorescence in-situ hybridization as a diagnostic tool for cutaneous melanoma].
Su J; Liu J; Zheng J; You J; Ma X; Zhang Y; Zhang J; Liao S
Zhonghua Bing Li Xue Za Zhi; 2015 Jan; 44(1):37-41. PubMed ID: 25765029
[TBL] [Abstract][Full Text] [Related]
33. Response to 'The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea'.
Choi JW; Lee ES
Br J Dermatol; 2020 Dec; 183(6):1149-1150. PubMed ID: 32762038
[No Abstract] [Full Text] [Related]
34. Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters.
Mohammedi L; Doula FD; Mesli F; Senhadji R
Afr Health Sci; 2019 Jun; 19(2):2140-2146. PubMed ID: 31656498
[TBL] [Abstract][Full Text] [Related]
35. Response to 'The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea' - reply from the authors.
Kim HS; Ahn HS
Br J Dermatol; 2020 Dec; 183(6):1150-1151. PubMed ID: 32767749
[No Abstract] [Full Text] [Related]
36. Is UV an etiological factor of acral melanoma?
Liu L; Zhang W; Gao T; Li C
J Expo Sci Environ Epidemiol; 2016 Nov; 26(6):539-545. PubMed ID: 26464096
[TBL] [Abstract][Full Text] [Related]
37. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.
Newell F; Wilmott JS; Johansson PA; Nones K; Addala V; Mukhopadhyay P; Broit N; Amato CM; Van Gulick R; Kazakoff SH; Patch AM; Koufariotis LT; Lakis V; Leonard C; Wood S; Holmes O; Xu Q; Lewis K; Medina T; Gonzalez R; Saw RPM; Spillane AJ; Stretch JR; Rawson RV; Ferguson PM; Dodds TJ; Thompson JF; Long GV; Levesque MP; Robinson WA; Pearson JV; Mann GJ; Scolyer RA; Waddell N; Hayward NK
Nat Commun; 2020 Oct; 11(1):5259. PubMed ID: 33067454
[TBL] [Abstract][Full Text] [Related]
38. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
39. [Genetic and epidemiological aspects of melanoma].
Bataille V
Ann Dermatol Venereol; 2006 Jan; 133(1):56-62. PubMed ID: 16495855
[No Abstract] [Full Text] [Related]
40. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
